Engineered cystine-knot miniproteins for diagnostic applications

Expert Review of Molecular Diagnostics

Volumn 10, Issue 3, 2010, Pages 361-368

  Kolmar, Harald ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cystine knot miniproteins; Integrin; PET imaging; Tumor diagnostics

Indexed keywords

CYSTINE KNOT MINIPROTEIN; PROTEIN; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CYSTINE KNOT MOTIF; DIAGNOSTIC PROCEDURE; HUMAN; IN VIVO STUDY; KIDNEY CLEARANCE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; TUMOR DIAGNOSIS;

AMINO ACID SEQUENCE; ANIMALS; CYSTINE KNOT MOTIFS; DISULFIDES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PATHOLOGY, MOLECULAR; PROTEIN CONFORMATION; PROTEINS;

EID: 77950607160     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.15     Document Type: Review

References (51)

1. Craik DJ, Daly NL. NMR as a tool for elucidating the structures of circular and knotted proteins. Mol. Biosyst. 3(4), 257-265 (2007).
2. Heitz A, Avrutina O, Le-Nguyen D et al. Knottin cyclization: impact on structure and dynamics. BMC Struct. Biol. 8, 54 (2008).
3. Wang CK, Hu SH, Martin JL et al. Combined x-ray and nmr analysis of the stability of the cyclotide cystine knot fold that underpins its insecticidal activity and potential use as drug scaffold. J. Biol. Chem. 284(16), 10672-10683 (2009).
4. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects. Cancer Res. 69(6), 2435-2442 (2009).
5. Werle M, Kafedjiiski K, Kolmar H, Bernkop-Schnürch A. Evaluation and improvement of the properties of the novel cystine-knot microprotein MCoEETI for oral administration. Int. J. Pharm. 332(1-2), 72-79 (2007). (Pubitemid 46227767)
6. Werle M, Schmitz T, Huang HL, Wentzel A, Kolmar H, Bernkop-Schnürch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J. Drug Target 14(3), 137-146 (2006). (Pubitemid 43878822)
7. Werle M, Kolmar H, Albrecht R, Bernkop-Schnürch A. Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot microproteins. Amino Acids 35(1), 195-200 (2008). (Pubitemid 351799193)
8. Gelly JC, Gracy J, Kaas Q, Le-Nguyen D, Heitz A, Chiche L. The knottin website and database: a new information system dedicated to the knottin scaffold. Nucleic Acids Res. 32(Database issue), D156-159 (2004).
9. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin. Pharmacother. 9(9), 1575-1583 (2008). (Pubitemid 352005917)
10. Massote PD, Pinheiro AC, Fonseca CG et al. Protective effect of retinal ischemia by blockers of voltage-dependent calcium channels and intracellular calcium stores. Cell Mol. Neurobiol. 28(6), 847-856 (2008).
11. Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Steinberg GK. SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci. 153(1), 25-31 (1997).
12. Azimi-Zonooz A, Kawa CB, Dowell CD, Olivera BM. Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of w-conotoxin MVIIa to attenuate neuronal injury after transient cerebral ischemia. Brain Res. 907(1-2), 61-70 (2001). (Pubitemid 32595512)
13. Chiche L, Heitz A, Gelly JC et al. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr. Protein Pept. Sci. 5(5), 341-349 (2004). (Pubitemid 39200164)
14. Craik DJ, Clark RJ, Daly NL. Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins. Expert Opin. Investig. Drugs 16(5), 595-604 (2007).
15. Blanco-Aparicio C, Molina MA, Fernandez- Salas E et al. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J. Biol. Chem. 273(20), 12370-12377 (1998). (Pubitemid 28240606)
16. Mas JM, Aloy P, Marti-Renom MA et al. Protein similarities beyond disulphide bridge topology. J. Mol. Biol. 284(3), 541-548 (1998). (Pubitemid 28550003)
17. Sitja-Arnau M, Molina MA, Blanco- Aparicio C et al. Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Lett. 226(2), 169-184 (2005). (Pubitemid 41039085)
18. Bolin KA, Anderson DJ, Trulson JA et al. NMR structure of a minimized human Agouti related protein prepared by total chemical synthesis. FEBS Lett. 451(2), 125-131 (1999).
19. Wilczynski AM, Joseph CG, Haskell- Luevano C. Current trends in the structure-activity relationship studies of the endogenous Agouti-related protein (AGRP) melanocortin receptor antagonist. Med. Res. Rev. 25(5), 545-556 (2005).
20. McNulty JC, Thompson DA, Bolin KA, Wilken J, Barsh GS, Millhauser GL. High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87-132) of the Agouti-related protein. Biochemistry 40(51), 15520-15527 (2001). (Pubitemid 34015179)
21. Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide AGRP(83-132) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28(3), 636-642 (2007). (Pubitemid 46205015)
22. Lahti JL, Silverman AP, Cochran JR. Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein. PLoS Comput. Biol. 5(9), e1000499 (2009).
23. Wentzel A, Christmann A, Krätzner R, Kolmar H. Sequence requirements of the GPNG b-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening. J. Biol. Chem. 274(30), 21037-21043 (1999). (Pubitemid 129519607)
24. Reiss S, Sieber M, Oberle V et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17(3), 153-157 (2006). (Pubitemid 43791626)
25. Sommerhoff CP, Schaschke N. Mast cell tryptase b as a target in allergic inflammation: an evolving story. Curr. Pharm. Des. 13(3), 313-332 (2007). (Pubitemid 46085281)
26. Avrutina O, Schmoldt HU, Gabrijelcic- Geiger D et al. Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis. Chembiochem 9(1), 33-37 (2008).
27. Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase b. J. Mol. Biol. 395(1), 167-175 (2010).
28. Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW. Potent inhibitors of b-tryptase and human leukocyte elastase based on the McoTI-II scaffold. J. Med. Chem. 52(20), 6197-6200 (2009).
29. Baggio R, Burgstaller P, Hale SP et al. Identification of epitope-like consensus motifs using mRNA display. J. Mol. Recognit. 15(3), 126-134 (2002).
30. Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind avb3 integrin with antibody-like affinities. J. Mol. Biol. 385(4), 1064-1075 (2009).
31. Schmoldt HU, Daneschdar M, Kolmar H, Blind M. Microbodies. Methods Mol. Biol. 535, 361-372 (2009).
32. Schmoldt HU, Wentzel A, Becker S, Kolmar H. A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle. Protein Expr. Purif. 39(1), 82-89 (2005). (Pubitemid 39645385)
33. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2(2), 91-100 (2002). (Pubitemid 37328796)
34. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7), 1157-1164 (1994).
35. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13(2), 113-135 (2006). (Pubitemid 44173112)
36. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12(22), 2723-2747 (2006). (Pubitemid 44184633)
37. Beer AJ, Haubner R, Sarbia M et al. Positron emission tomography using [18F] galacto-rgd identifies the level of integrin avb3 expression in man. Clin. Cancer Res. 12(13), 3942-3949 (2006).
38. Haubner R, Weber WA, Beer AJ et al. Noninvasive visualization of the activated avb3 integrin in cancer patients by positron emission tomography and [18F]galacto- RGD. PLoS Med. 2(3), e70 (2005).
39. Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind avb3, avb5, and a5b1 integrins with low-nanomolar affinity. Proteins 77(2), 359-369 (2009).
40. Miao Z, Ren G, Liu H et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug. Chem. 20(12), 2342-2347 (2009).
41. Li ZB, Cai W, Cao Q et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal pet of tumor avb3 integrin expression. J. Nucl. Med. 48(7), 1162-1171 (2007).
42. Liu S. Radiolabeled cyclic RGD peptides as integrin avb3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem. 20(12), 2199-2213 (2009).
43. Kolmar H, Skerra A. Alternative binding proteins get mature: rivalling antibodies. FEBS. J. 275(11), 2667 (2008).
44. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8(10), 2861-2871 (2009).
45. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60(12), 1421-1434 (2008).
46. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29(2), 57-61 (2008).
47. Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J. 274(1), 86-95 (2007). (Pubitemid 44952900)
48. Greenwood KP, Daly NL, Brown DL, Stow JL, Craik DJ. The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis. Int. J. Biochem. Cell Biol. 39(12), 2252-2264 (2007).
49. Craik DJ, Daly NL, Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon 39(1), 43-60 (2001). (Pubitemid 30628928)
50. Maillere B, Mourier G, Herve M, Cotton J, Leroy S, Menez A. Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 33(4), 475-482 (1995).
51. Avrutina O, Schmoldt HU, Gabrijelcic- Geiger D et al. Trypsin inhibition by macrocyclic and open-chain variants of the squash inhibitor MCoTI-II. Biol. Chem. 386(12), 1301-1306 (2005). (Pubitemid 41794058)